ThromboGenics NV has entered into an agreement with Alcon, a division of Novartis, for the commercialization of ocriplasmin in all markets outside the U.S. ThromboGenics will focus on commercializing ocriplasmin in the U.S., where it plans to build its commercial and medical organization to support the anticipated product launch. The two companies will also work together and share costs to develop new clinical applications of the product to introduce in their respective territories.

ThromboGenics will receive an upfront payment of €75 million and an additional €90 million in potential milestone payments. Total milestones have the potential to reach €375 million. ThromboGenics will also receive royalties on sales of ocriplasmin, if approved. ThromboGenics will commercialize ocriplasmin in the five largest European markets.

ThromboGenics has completed a development program, including two successful Phase III studies that have shown that ocriplasmin plays an important role in treating symptomatic VMA, an increasingly recognized sight-threatening disease of the vitreoretinal interface.

Dr. Patrik De Haes, chief executive officer of ThromboGenics, said, “This collaborative deal with Alcon to commercialize ocriplasmin outside of the U.S. is a major milestone for ThromboGenics. Alcon is the ideal partner for an innovative retinal therapy given its global sales, marketing and medical capabilities in the ophthalmic market and its commitment to making ocriplasmin a success. We are now concentrating on bringing ocriplasmin to the U.S. market ourselves and are building the commercial and medical organization needed to support the product’s anticipated launch.”

Kevin Buehler, division head of Alcon, said, “There are thousands of symptomatic vitreomacular adhesion patients who currently do not have an available treatment option. The clinical results for ocriplasmin show improved visual function and that earlier intervention may limit the progression of the disease,” said Kevin Buehler, division head for Alcon. “Ocriplasmin is a strategic fit for Alcon and is expected to further enhance our portfolio of innovative treatments for the eye.”